» Articles » PMID: 11389700

Inhibition of Peroxisome-proliferator-activated Receptor (PPAR)alpha by MK886

Overview
Journal Biochem J
Specialty Biochemistry
Date 2001 Jun 8
PMID 11389700
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Although MK886 was originally identified as an inhibitor of 5-lipoxygenase activating protein (FLAP), recent data demonstrate that this activity does not underlie its ability to induce apoptosis [Datta, Biswal and Kehrer (1999) Biochem. J. 340, 371--375]. Since FLAP is a fatty-acid binding protein, it is conceivable that MK886 may affect other such proteins. A family of nuclear receptors that are activated by fatty acids and their metabolites, the peroxisome-proliferator-activated receptors (PPARs), have been implicated in apoptosis and may represent a target for MK886. The ability of MK886 to inhibit PPAR-alpha, -beta and -gamma activity was assessed using reporter assay systems (peroxisome-proliferator response element--luciferase). Using a transient transfection system in monkey kidney fibroblast CV-1 cells, mouse keratinocyte 308 cells and human lung adenocarcinoma A549 cells, 10--20 microM MK886 inhibited Wy14,643 activation of PPAR alpha by approximately 80%. Similar inhibition of PPAR alpha by MK886 was observed with a stable transfection reporter system in CV-1 cells. Only minimal inhibitory effects were seen on PPAR beta and PPAR gamma. MK886 inhibited PPAR alpha by a non-competitive mechanism as shown by its effects on the binding of arachidonic acid to PPAR alpha protein, and a dose-response study using a transient transfection reporter assay in COS-1 cells. An assay assessing PPAR ligand-receptor interactions showed that MK886 prevents the conformational change necessary for active-complex formation. The expression of keratin-1, a protein encoded by a PPAR alpha-responsive gene, was reduced by MK886 in a culture of mouse primary keratinocytes, suggesting that PPAR inhibition has functional consequences in normal cells. Although Jurkat cells express all PPAR isoforms, various PPAR alpha and PPAR gamma agonists were unable to prevent MK886-induced apoptosis. This is consistent with MK886 functioning as a non-competitive inhibitor of PPAR alpha, but may also indicate that PPAR alpha is not directly involved in MK886-induced apoptosis. Although numerous PPAR activators have been identified, the results show that MK886 can inhibit PPAR alpha, making it the first compound identified to have such an effect.

Citing Articles

Discovery of PPAR Alpha Lipid Pathway Modulators That Do Not Bind Directly to the Receptor as Potential Anti-Cancer Compounds.

Al Subait A, Alghamdi R, Ali R, Alsharidah A, Huwaizi S, Alkhodier R Int J Mol Sci. 2025; 26(2).

PMID: 39859448 PMC: 11766124. DOI: 10.3390/ijms26020736.


USP25 directly interacts with and deubiquitinates PPARα to increase PPARα stability in hepatocytes and attenuate high-fat diet-induced MASLD in mice.

Jin L, Zhu W, Hu X, Ye L, Lou S, Zhang Q Cell Death Differ. 2025; .

PMID: 39827322 DOI: 10.1038/s41418-025-01444-4.


Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice.

Keever K, Askari B Curr Res Pharmacol Drug Discov. 2024; 7:100203.

PMID: 39497763 PMC: 11532750. DOI: 10.1016/j.crphar.2024.100203.


2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.

Pan B, Chen Z, Zhang X, Wang Z, Yao Y, Wu X J Immunother Cancer. 2023; 11(6).

PMID: 37316264 PMC: 10277542. DOI: 10.1136/jitc-2023-006817.


Vitamin D improves hepatic steatosis in NAFLD regulation of fatty acid uptake and β-oxidation.

Du T, Xiang L, Zhang J, Yang C, Zhao W, Li J Front Endocrinol (Lausanne). 2023; 14:1138078.

PMID: 37033263 PMC: 10074590. DOI: 10.3389/fendo.2023.1138078.


References
1.
He T, Chan T, Vogelstein B, Kinzler K . PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999; 99(3):335-45. PMC: 3779681. DOI: 10.1016/s0092-8674(00)81664-5. View

2.
Tang D, Chen Y, Honn K . Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A. 1996; 93(11):5241-6. PMC: 39229. DOI: 10.1073/pnas.93.11.5241. View

3.
Hasmall S, James N, Macdonald N, Gonzalez F, Peters J, Roberts R . Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha. Mutat Res. 2000; 448(2):193-200. DOI: 10.1016/s0027-5107(99)00236-5. View

4.
Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M . Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2001; 270(2):400-5. DOI: 10.1006/bbrc.2000.2436. View

5.
Chattopadhyay N, Singh D, Heese O, Godbole M, Sinohara T, Black P . Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res. 2000; 61(1):67-74. DOI: 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7. View